ClinicalTrials.gg
CompletedNCT02414594Updated Dec 5, 2018

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

A Phase 1 interventional study of IONIS-APO(a)-LRx and Sterile Normal Saline (0.9% NaCl) in Elevated Lipoprotein(a), sponsored by Ionis Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-05.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APO(a)-LRx (ISIS 681257) given to healthy volunteer subjects.

02

Conditions studied

  • Elevated Lipoprotein(a)
03

In context

Lead sponsor

Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have given written and be able to comply with all study requirements
  • Healthy males or females aged 18-65 inclusive and weighing ≥ 50 kg at the time of informed consent
  • Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal
  • Males must be surgically sterile, abstinent or using an acceptable method
  • \< 35.0 kg/m2
  • Subjects must have Lp(a) ≥ 75 nanomoles/liter nmol/L (30 mg/dL) at Screening

Exclusion criteria

Exclusion Criteria:

  • Known history of or positive test for (HIV), or chronic
  • Treatment with another Study Drug, biological agent, or device within one-month of screening
  • Regular use of alcohol within 6 months of Screening
  • Use of concomitant drugs unless authorized by the Sponsor Medical Monitor
  • Smoking > 10 cigarettes a day
  • Considered unsuitable for inclusion by the Principal Investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    IONIS-APO(a)-LRx

    Drug: IONIS-APO(a)-LRx

    Drug: IONIS-APO(a)-LRx

  • Placebo comparator
    Placebo (Normal Saline)

    Drug: Sterile Normal Saline (0.9% NaCl)

    Drug: Sterile Normal Saline (0.9% NaCl)

Interventions

  • Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection

  • DrugSterile Normal Saline (0.9% NaCl)

    Calculated volume to match active comparator

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of single and multiple doses of IONIS-APO(a)-LRx (incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters)

    The safety and tolerability of IONIS-APO(a)-LRx will be assessed by determining the incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters by dose. Safety results in subjects dosed with IONIS-APO(a)-LRx will be compared with those from subjects dosed with placebo.

    Time frame: Up to 113 days

  2. To evaluate the pharmacokinetics of single and multiple doses of IONIS-APO(a)-LRx (unconjugated and conjugated ASO)

    The plasma pharmacokinetics of IONIS-APO(a)-LRx (unconjugated and conjugated ASO) will be assessed following single and multiple-dose SC administration. The amount of ISIS-APO(a)-LRx excreted in urine at selected 24-hour intervals will also be determined.

    Time frame: Up to 113 days

  3. To evaluate the plasma pharmacodynamics of IONIS-APO(a)-LRx (Changes in plasma Lp(a) levels)

    Changes in plasma Lp(a) levels compared to baseline.

    Time frame: Up to 113 days

Secondary outcomes

  1. Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx

    Effects of IONIS-APO(a)-LRx on changes in levels of oxidized phospholipids associated with apoB-100 compared to baseline.

    Time frame: Up to 113 days

  2. Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx

    Effects of IONIS-APO(a)-LRx on changes in levels of oxidized phospholipids associated with apo(a) compared to baseline.

    Time frame: Up to 113 days

  3. Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx

    Effects of IONIS-APO(a)-LRx on changes in Lp-PLA2 compared to baseline.

    Time frame: Up to 113 days

  4. Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx

    Effects of IONIS-APO(a)-LRx on changes in sPLA2 compared to baseline.

    Time frame: Up to 113 days

  5. Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx

    Effects of IONIS-APO(a)-LRx on changes in apo(a) isoform size compared to baseline.

    Time frame: Up to 113 days

  6. Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx

    Effects of ISIS-APO(a)-LRx on changes in lipid panel compared to baseline.

    Time frame: Up to 113 days

  7. Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx

    Effects of IONIS-APO(a)-LRx on changes in systemic markers of inflammation compared to baseline.

    Time frame: Up to 113 days

  8. Exploratory pharmacodynamic effects of IONIS-APO(a)-LRx

    Effects of IONIS-APO(a)-LRx on changes in plasminogen/coagulation compared to baseline.

    Time frame: Up to 113 days

07

Study locations

1 site
  • Clinical Site
    Toronto, Ontario M9L 3A2, Canada
08

References and documents

Publications

  • Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21. PubMed 27665230 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2015
First posted
Apr 13, 2015
Start
Apr 2015
Primary completionActual
Feb 2016
CompletionActual
Feb 2016
Last update
Dec 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02414594
Collaborators
Akcea Therapeutics
Responsible party
Sponsor
First posted
Apr 13, 2015
Start date
Apr 2015
Primary completion
Feb 2016
Completion
Feb 2016
Last update
Dec 5, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelacarsen

Start the discussion